Current HIV/AIDS Reports

, Volume 15, Issue 1, pp 84–91 | Cite as

CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose

  • Andrea Calcagno
  • Ambra Barco
  • Mattia Trunfio
  • Stefano Bonora
Central Nervous System and Cognition (SS Spudich, Section Editor)
  • 178 Downloads
Part of the following topical collections:
  1. Topical Collection on Central Nervous System and Cognition

Abstract

Purpose of Review

Neurocognitive disorders are not uncommon in HIV-positive patients but their pathogenesis is multifactorial and incompletely understood. After excluding contributing comorbidities, several factors may impair neurocognition including severe immune suppression, incomplete antiviral efficacy, drugs' persistent immune activation, vascular abnormalities, and drugs' neurotoxicity. The effectiveness of targeted antiretroviral strategies on these risk factors is unknown.

Recent Findings

Recent studies support the idea that residual cerebrospinal fluid HIV RNA in the setting of plasma viral suppression is associated with compartmental immune activation but the link to neuronal damage is debated. Some authors have reported an incomplete antiviral efficacy in macrophage-derived cells but targeted antiretroviral regimen switches have not been performed. Additionally, improvements in neurocognition using drugs with better central nervous system penetration or maraviroc (associated with favorable immunological properties) have been observed in pilot studies. Trials evaluating specific interventions for cardiovascular health (including brain white matter abnormalities) and neurotoxicity of antiretrovirals are warranted.

Summary

Central nervous system-targeted antiretroviral strategies are needed in patients with uncontrolled cerebrospinal HIV replication, and they may be suggested in subjects with low CD4 nadir, individuals carrying drug-resistant viruses, and those with compartmental immune activation.

Keywords

HIV-associated neurocognitive disorders Cerebrospinal fluid Antiretrovirals Pharmacokinetics Pharmacodynamics Compartmentalization 

Notes

Compliance with Ethical Standards

Conflict of Interest

Andrea Calcagno received research grants from Gilead, BMS, and Viiv and has received payment for lectures from Abbvie, BMS, Gilead, Janssen-Cilag, MSD, and Viiv.

Stefano Bonora received research grants from Gilead, BMS, and Viiv and has received payment for lectures from Abbvie, BMS, Gilead, Janssen-Cilag, MSD, and Viiv.

Ambra Barco and Mattia Trunfio have no conflict of interest to declare.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Hogg RS, Eyawo O, Collins AB, Zhang W, Jabbari S, Hull MW, et al. Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study. Lancet HIV. 2017;2.Google Scholar
  2. 2.
    Haddow LJ, Laverick R, Daskalopoulou M, McDonnell J, Lampe FC, Gilson R, et al. Multicenter European prevalence study of neurocognitive impairment and associated factors in HIV positive patients. AIDS Behav. 2017.Google Scholar
  3. 3.
    •• Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13(11):1139–51.  https://doi.org/10.1016/S1474-4422(14)70137-1. An in-depth and balanced review on the pathogenesis, risk factors and management of HIV-associated neurocognitive disorders.CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Johnson TP, Patel K, Johnson KR, Maric D, Calabresi PA, Hasbun R, et al. Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A. 2013;110(33):13588–93.  https://doi.org/10.1073/pnas.1308673110.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087–96.  https://doi.org/10.1212/WNL.0b013e318200d727.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Curley P, Rajoli RKR, Moss DM, Liptrott NJ, Letendre S, Owen A, et al. Efavirenz is predicted to accumulate in brain tissue: an in silico, in vitro, and in vivo investigation. Antimicrob Agents Chemother. 2017;61(1).Google Scholar
  7. 7.
    Mallard J, Rife B, Papazian E, Noggle A, Nolan DJ, Salemi M, et al. CNS parenchyma and choroid plexus, not CSF, are viral reservoirs in monkeys with aids. In the abstract book of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA; 2017.Google Scholar
  8. 8.
    Motta I, Allice T, Romito A, Ferrara M, Ecclesia S, Imperiale D, et al. Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia. Antivir Ther. 2017.Google Scholar
  9. 9.
    Edén A, Marcotte TD, Heaton RK, Nilsson S, Zetterberg H, Fuchs D, et al. Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment. PLoS One. 2016;11(6):e0157160.  https://doi.org/10.1371/journal.pone.0157160.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Bai F, Iannuzzi F, Merlini E, Borghi L, Tincati C, Trunfio M, et al. Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients. AIDS Lond Engl. 2017;31(2):311–4.  https://doi.org/10.1097/QAD.0000000000001346.CrossRefGoogle Scholar
  11. 11.
    Ferretti F, Gisslen M, Cinque P, Price RW. Cerebrospinal fluid HIV escape from antiretroviral therapy. Curr HIV/AIDS Rep. 2015;12(2):280–8.  https://doi.org/10.1007/s11904-015-0267-7.CrossRefPubMedGoogle Scholar
  12. 12.
    •• Edén A, Nilsson S, Hagberg L, Fuchs D, Zetterberg H, Svennerholm B, et al. Asymptomatic cerebrospinal fluid HIV-1 viral blips and viral escape during antiretroviral therapy: a longitudinal study. J Infect Dis. 2016. A longitudinal study assessing the outcome of detectable CSF HIV RNA: the results support the concept of CSF blips whose clinical relevance is still debated.Google Scholar
  13. 13.
    Anderson AM, Muñoz-Moreno JA, McClernon DR, Ellis RJ, Cookson D, Clifford DB, et al. Prevalence and correlates of persistent HIV-1 RNA in cerebrospinal fluid during antiretroviral therapy. J Infect Dis. 2017;215(1):105–13.  https://doi.org/10.1093/infdis/jiw505.CrossRefPubMedGoogle Scholar
  14. 14.
    Yilmaz A, Verhofstede C, D’Avolio A, Watson V, Hagberg L, Fuchs D, et al. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr 1999. 2010;55(5):590–6.  https://doi.org/10.1097/QAI.0b013e3181f5b3d1.CrossRefGoogle Scholar
  15. 15.
    Canestri A, Lescure F-X, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;50(5):773–8.  https://doi.org/10.1086/650538.CrossRefGoogle Scholar
  16. 16.
    Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS Lond Engl. 2012;26(14):1765–74.  https://doi.org/10.1097/QAD.0b013e328355e6b2.CrossRefGoogle Scholar
  17. 17.
    Garvey LJ, Pavese N, Politis M, Ramlackhansingh A, Brooks DJ, Taylor-Robinson SD, et al. Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. AIDS Lond Engl. 2014;28(1):67–72.  https://doi.org/10.1097/01.aids.0000432467.54003.f7.CrossRefGoogle Scholar
  18. 18.
    Gavegnano C, Schinazi RF. Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother. 2009;20(2):63–78.  https://doi.org/10.3851/IMP1374.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Shikuma CM, Nakamoto B, Shiramizu B, Liang C-Y, DeGruttola V, Bennett K, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther. 2012;17(7):1233–42.  https://doi.org/10.3851/IMP2411.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Mora-Peris B, Winston A, Garvey L, Else LJ, Shattock RJ, Herrera C. HIV-1 CNS in vitro infectivity models based on clinical CSF samples. J Antimicrob Chemother. 2016;71(1):235–43.  https://doi.org/10.1093/jac/dkv326.CrossRefPubMedGoogle Scholar
  21. 21.
    Bryant AK, Moore DJ, Burdo TH, Lakritz JR, Gouaux B, Soontornniyomkij V, et al. Plasma soluble CD163 is associated with postmortem brain pathology in human immunodeficiency virus infection. AIDS Lond Engl. 2017;31(7):973–9.  https://doi.org/10.1097/QAD.0000000000001425.CrossRefGoogle Scholar
  22. 22.
    Schrier RD, Hong S, Crescini M, Ellis R, Pérez-Santiago J, Spina C, et al. Cerebrospinal fluid (CSF) CD8+ T-cells that express interferon-gamma contribute to HIV associated neurocognitive disorders (HAND). PLoS One. 2015;10(2):e0116526.  https://doi.org/10.1371/journal.pone.0116526.CrossRefPubMedCentralPubMedGoogle Scholar
  23. 23.
    Calcagno A, Romito A, Atzori C, Ghisetti V, Cardellino C, Audagnotto S, et al. Blood brain barrier impairment in HIV-positive naïve and effectively treated patients: immune activation versus astrocytosis. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol. 2017;12(1):187–93.  https://doi.org/10.1007/s11481-016-9717-2.CrossRefGoogle Scholar
  24. 24.
    Martin-Blondel G, Brassat D, Bauer J, Lassmann H, Liblau RS. CCR5 blockade for neuroinflammatory diseases—beyond control of HIV. Nat Rev Neurol. 2016;12(2):95–105.  https://doi.org/10.1038/nrneurol.2015.248.CrossRefPubMedGoogle Scholar
  25. 25.
    Thompson M, Saag M, DeJesus E, Gathe J, Lalezari J, Landay AL, et al. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS Lond Engl. 2016;30(6):869–78.  https://doi.org/10.1097/QAD.0000000000000988.CrossRefGoogle Scholar
  26. 26.
    Underwood J, Robertson KR, Winston A. Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease? AIDS Lond Engl. 2015;29(3):253–61.  https://doi.org/10.1097/QAD.0000000000000538.CrossRefGoogle Scholar
  27. 27.
    Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neuro-Oncol. 2012;18(5):388–99.Google Scholar
  28. 28.
    Soontornniyomkij V, Umlauf A, Chung SA, Cochran ML, Soontornniyomkij B, Gouaux B, et al. HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS Lond Engl. 2014;28(9):1297–306.  https://doi.org/10.1097/QAD.0000000000000262.CrossRefGoogle Scholar
  29. 29.
    Su T, Wit FWNM, Caan MWA, Schouten J, Prins M, Geurtsen GJ, et al. White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on combination antiretroviral therapy. AIDS Lond Engl. 2016;30(15):2329–39.  https://doi.org/10.1097/QAD.0000000000001133.CrossRefGoogle Scholar
  30. 30.
    Hammond ER, Crum RM, Treisman GJ, Mehta SH, Marra CM, Clifford DB, et al. The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV. Am J Epidemiol. 2014;180(3):297–307.  https://doi.org/10.1093/aje/kwu098.CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Hammond ER, Crum RM, Treisman GJ, Mehta SH, Clifford DB, Ellis RJ, et al. Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study. J Neuro-Oncol. 2016 Aug;22(4):479–87.Google Scholar
  32. 32.
    Ellis RJ, Letendre S, Vaida F, Haubrich R, Heaton RK, Sacktor N, et al. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;58(7):1015–22.  https://doi.org/10.1093/cid/cit921.CrossRefGoogle Scholar
  33. 33.
    Vassallo M, Durant J, Biscay V, Lebrun-Frenay C, Dunais B, Laffon M, et al. Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? AIDS Lond Engl. 2014;28(4):493–501.  https://doi.org/10.1097/QAD.0000000000000096.CrossRefGoogle Scholar
  34. 34.
    Cross HM, Combrinck MI, Joska JA. HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. 2013;103(10):758–62.Google Scholar
  35. 35.
    Force G, Hahn V, Defferriere H, Darchy N, Ropers J, Aegerter P, et al. Week48 cognitive improvement in HAND after switch to HAART based on CHARTER score +3. In the abstract book of the Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA; 2016.Google Scholar
  36. 36.
    Calcagno A, Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S, et al. Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;60(2):311–7.  https://doi.org/10.1093/cid/ciu773.CrossRefGoogle Scholar
  37. 37.
    Aquaro S, Svicher V, Schols D, Pollicita M, Antinori A, Balzarini J, et al. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J Leukoc Biol. 2006;80(5):1103–10.  https://doi.org/10.1189/jlb.0606376.CrossRefPubMedGoogle Scholar
  38. 38.
    Winston A, Puls R, Kerr SJ, Duncombe C, Li P, Gill JM, et al. Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART. PLoS One. 2015;10(2):e0118608.  https://doi.org/10.1371/journal.pone.0118608.CrossRefPubMedCentralPubMedGoogle Scholar
  39. 39.
    Zhang F, Heaton R, Wu H, Jin H, Zhao H, Yu X, Franklin D, Mu W, Vaida F, Letendre S. Randomized clinical trial of antiretroviral therapy for prevention of HAND. In the abstract book of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA; 2015.Google Scholar
  40. 40.
    Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010;74(16):1260–6.  https://doi.org/10.1212/WNL.0b013e3181d9ed09.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;59(7):1032–7.  https://doi.org/10.1093/cid/ciu477.CrossRefGoogle Scholar
  42. 42.
    Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, et al. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. J Antimicrob Chemother. 2013;68(11):2525–32.  https://doi.org/10.1093/jac/dkt220.CrossRefPubMedGoogle Scholar
  43. 43.
    Hinckley S, Sherman S, Best BM, Momper J, Ma Q, Letendre SR, et al. Neurotoxicity screening of antiretroviral drugs with human iPSC-derived neurons. In the abstract book of the Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA; 2016.Google Scholar
  44. 44.
    Akay-Espinoza C, Stern AL, Nara RL, Panvelker N, Li J, Jordan-Sciutto KL. Differential in vitro neurotoxicity of antiretroviral drugs. In the abstract book of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA; 2017.Google Scholar
  45. 45.
    Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink H-J, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63.  https://doi.org/10.1111/hiv.12468.CrossRefPubMedGoogle Scholar
  46. 46.
    Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, et al. Psychiatric symptoms in patients receiving dolutegravir. J Acquir Immune Defic Syndr 1999. 2017;74(4):423–31.  https://doi.org/10.1097/QAI.0000000000001269.CrossRefGoogle Scholar
  47. 47.
    Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS Lond Engl. 2016 Feb 20;30(4):591–600.  https://doi.org/10.1097/QAD.0000000000000951.CrossRefGoogle Scholar
  48. 48.
    • Nightingale S, Geretti AM, Beloukas A, Fisher M, Winston A, Else L, et al. Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. J Neurovirol. 2016. A relevant cross-sectional study showing the prevalence of CSF escape in patients with low level viremia in the past 12 months (18%) versus those with durable virological suppression (0%).Google Scholar
  49. 49.
    Ritola K, Robertson K, Fiscus SA, Hall C, Swanstrom R. Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol. 2005;79(16):10830–4.  https://doi.org/10.1128/JVI.79.16.10830-10834.2005.CrossRefPubMedCentralPubMedGoogle Scholar
  50. 50.
    Clarke A, Johanssen V, Gerstoft J, Clotet B, Ripamonti D, Murungi A, et al. Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues. J Int AIDS Soc. 2014;17(4 Suppl 3):19526.  https://doi.org/10.7448/IAS.17.4.19526.CrossRefPubMedCentralPubMedGoogle Scholar
  51. 51.
    Fabbiani M, Grima P, Milanini B, Mondi A, Baldonero E, Ciccarelli N, et al. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility. Antivir Ther. 2015;20(4):441–7.  https://doi.org/10.3851/IMP2926.CrossRefPubMedGoogle Scholar
  52. 52.
    Ameet D, et al. Cerebrospinal fluid (CSF) HIV escape is associated with progressive neurologic deterioration in patients on virologically suppressive antiretroviral therapy (ART) in Western India. In the Abstract book of the European AIDS Conference, Barcelona, Spain; 2015.Google Scholar
  53. 53.
    Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology. 2011 Apr 19;76(16):1403–9.  https://doi.org/10.1212/WNL.0b013e31821670fb.CrossRefPubMedGoogle Scholar
  54. 54.
    Hammarlund GO, Edén A, Mellgren Å, Fuchs D, Zetterberg H, Hagberg L, et al. CNS inflammation still present after >10 years of effective antiretroviral therapy. In the abstract book of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA; 2017.Google Scholar
  55. 55.
    •• Kugathasan R, Collier DA, Haddow LJ, El Bouzidi K, Edwards SG, Cartledge JD, et al. Diffuse white matter signal abnormalities on magnetic resonance imaging are associated with human immunodeficiency virus type 1 viral escape in the central nervous system among patients with neurological symptoms. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017;64(8):1059–65.  https://doi.org/10.1093/cid/cix035. An interesting study on brain White Matter Abnormalities showing an association with CSF discordance/escape: these data may support a role for HIV replication and inflammation in the pathogenesis of white matter injury.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Andrea Calcagno
    • 1
  • Ambra Barco
    • 1
  • Mattia Trunfio
    • 1
  • Stefano Bonora
    • 1
  1. 1.Unit of Infectious Diseases, Department of Medical SciencesUniversity of TorinoTurinItaly

Personalised recommendations